Key result
Neoagaro-oligosaccharides significantly reduced visceral fat area, visceral-subcutaneous fat area ratio, body weight, and BMI compared to placebo over 16 weeks in overweight and obese women.
Why the study?
This trial aimed to evaluate the anti-obesity effects and safety of Neoagaro-oligosaccharide in humans.
Does Neoagaro-oligosaccharides (NAOs) reduce visceral fat and body weight in overweight and obese adults?
RCT (n=100)
Double-blind
1:1
No
Does Neoagaro-oligosaccharides (NAOs) reduce visceral fat and body weight in overweight and obese adults?
Neoagaro-oligosaccharides (NAOs) supplementation for 16 weeks significantly reduced visceral fat area, visceral-subcutaneous fat area ratio, body weight, and BMI in overweight and obese adults compared to placebo.
Answers are grounded in this paper and cite their sources.
May aid visceral fat reduction in overweight adults; provides first human RCT evidence for NAOs in obesity.
Background This trial aimed to evaluate the anti-obesity effects and safety of Neoagaro-oligosaccharide (NAOs) in humans in a 16 week, randomized, double-blind, placebo-controlled clinical trial. Methods A total of 100 overweight or obese subjects with a body mass index (BMI) of 23 to 34.9 kg/m 2 and a body fat percentage of > 25% for males or > 30% for females were enrolled. NAOs or placebo products were administered at 3 g each for 16 weeks. Efficacy and safety biomarkers were measured before and after intervention. Results After 16 weeks of intervention, the group administered with NAOs had statistically significant decreases of visceral fat area (VFA), visceral-subcutaneous fat area ratio (VSR), weight, and BMI compared to the placebo group. High-density lipoprotein- cholesterol (HDL-C) was increased in the group administered with NAOs, which showed a significant trend compared to the placebo group. Clinical changes were not observed for any safety biomarkers. Conclusions These results suggest that NAOs have a beneficial effect on obesity. Thus, NAOs could be used as an anti-obesity supplement without side effects. Trial registration: cris.nih.go.kr: (KCT0006640, 07/10/2021).
No takes yet. Share an insight, caveat, or question.
Baek et al. (2023) conducted an RCT in Overweight and obesity (n=100). Neoagaro-oligosaccharides (NAOs) vs. Placebo (corn starch) was evaluated on Change in visceral fat area (VFA) in mm2 (p=0.021). Neoagaro-oligosaccharides significantly reduced visceral fat area, visceral-subcutaneous fat area ratio, body weight, and BMI compared to placebo over 16 weeks in overweight and obese women.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: